eXoZymes closed at $4.11 on Nov 5, down 4.64%, 75.1% below its 52-week closing high. Volume of 6.6K shares was 0.48× its 20-day average (below normal).
Split-adjusted performance: -25.8% over one month, -58.9% over six months.
Short interest was 17.7K shares at the Oct 15 settlement, down 4.4% from the prior report (0.7% of float, 1.9 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| EXOZeXoZymes | $4.11 | −4.64% | −58.9% | — | — | — | $38.2M | |
| PTHSPelthos Therapeutics | $9.55 | −5.91% | −61.8% | — | −150.1% | — | $37.5M | Compare |
| INMBINmune Bio | $1.19 | −10.53% | −16.8% | — | — | — | $36.8M | Compare |
| LONALeonaBio | $4.32 | −5.40% | −56.2% | — | — | — | $40.7M | Compare |
| CRBUCaribou Biosciences | $0.4069 | −8.44% | −78.4% | −43.8% | −1619.9% | — | $43.6M | Compare |
| ELUTElutia | $0.7330 | −3.50% | −26.6% | −11.6% | −315.0% | 0.6 | $32.5M | Compare |
| IMAImageneBio | $4.08 | −0.49% | −31.0% | — | — | — | $46.3M | Compare |
| TILInstil Bio | $6.97 | −0.29% | −13.2% | — | — | — | $47.3M | Compare |
| GRMLGreenland Mines | $3.62 | −7.42% | — | — | — | — | $49.5M | Compare |
No recent articles focused on eXoZymes.
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods. The company believes its platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than the typical methods used today, such as chemical synthesis, natural extraction, and synthetic biology.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
